search
Back to results

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

Primary Purpose

Pediculosis Capitis, Lice Infestations, Head Lice

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Vamousse Spray 'n' Go
Nix Creme Rinse Lice Treatment
Sponsored by
Alliance Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pediculosis Capitis

Eligibility Criteria

2 Years - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects must have an active head lice infestation defined as: at least 1 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator.
  • Subjects must be at least two (2) years of age through 75 years of age, presenting with an active head lice infestation.
  • Subject is male or female.
  • Subject is in good general health based on medical history.
  • Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children 6-17 years of age will be administered a child's Assent Form.
  • The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in receiving study product or Standard of Care.
  • Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study.
  • Following application of the test product, subject agrees not to shampoo, wash or rinse their hair or scalp until 8-hour post-treatment time has been reached and documented.
  • Subject agrees not to cut or chemically treat their hair while participating in the study.
  • Subject agrees to follow all study instructions, including attending all follow-up appointments.
  • Female subjects of childbearing potential must be willing to have a urine pregnancy test prior to inclusion in this study.

Exclusion Criteria:

  • History of irritation or sensitivity to Vamousse Spray 'n' Go or the components, pediculicides or hair care products.
  • Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or medical monitor, will interfere with safety and/or efficacy evaluations.
  • Presentation at the treatment site with eczema or atopic dermatitis.
  • Treatment for head lice (Over the Counter [OTC], home remedy and/or Prescription) in the last 30 days.
  • Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.
  • Is receiving any other treatment which, in the opinion of the investigator or medical monitor, may interfere with the study results.
  • Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy which could include household subjects. If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation and provided Standard of Care.
  • Household members of child-bearing potential, including subjects, and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomised partner, oral birth control pills, birth control injections or patches, intra uterine devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilisation. Subjects and/or caregivers will be considered non-child-bearing if the following has occurred: full hysterectomy or bilateral oophorectomy is considered surgically sterile. Tubal ligation is not considered equivalent to female sterilisation.
  • Participation in a previous investigational drug study within the past 30 days.
  • Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.
  • Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house of apartment unit).

Sites / Locations

  • South Florida Family Health and Research Centers, LLC.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Vamousse Spray 'n' Go

Nix Creme Rinse Lice Treatment

Arm Description

Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.

During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.

Outcomes

Primary Outcome Measures

The proportion of subjects in a study group who are completely lice free.
Lice free is defined as no live lice, adults or nymphs.

Secondary Outcome Measures

The change in total number of live adult lice and nymphs from the baseline count in each study group.

Full Information

First Posted
September 30, 2022
Last Updated
January 26, 2023
Sponsor
Alliance Pharmaceuticals
Collaborators
South Florida Family Health and Research Centers
search

1. Study Identification

Unique Protocol Identification Number
NCT05565820
Brief Title
A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation
Official Title
Treatment of Infestation With Pediculus Humanus Capitis in the Community Using a leave-in Spray: A Prospective, Randomised Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2022 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alliance Pharmaceuticals
Collaborators
South Florida Family Health and Research Centers

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the safety and efficacy of Vamousse Spray 'n' Go, compared to a 1% Permethrin control shampoo, in the treatment of head lice.
Detailed Description
Effective methods for eradication of lice infestation are available however many are time consuming to use and require diligence; ineffective application of treatments has led to the spread of resistant strains. This is a post-marketing, prospective, open label, randomised controlled study to evaluate the safety and efficacy of Vamousse Spray 'n' Go in subjects infested with Pediculosis Capitis. The product contains a broad spectrum antiparasitic, which may have a unique mode of action, and has a simple and convenient application method. The primary objective of the study will explore whether treatment with Vamousse Spray 'n' Go is more effective in killing lice and eggs compared to a permethrin-based control product. The secondary objective of the study is to demonstrate the safety and local tolerability of Vamousse Spray 'n' Go in children ages 2 years plus. The planned sample size is 58 subjects, equally split between treatment and control groups. Subjects will receive the allocated product on day 0, with follow-up visits on days 2, 7 and 14. A repeat treatment will be administered on day 7 if live lice are still present.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pediculosis Capitis, Lice Infestations, Head Lice

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Parallel group design with participants randomised 1:1 to Vamousse Spray 'n' Go or 1% Permethrin control.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Vamousse Spray 'n' Go
Arm Type
Experimental
Arm Description
Clinical staff will apply Vamousse Spray 'n' Go during the baseline visit (Day 0) to fully coat the hair and scalp. The treatment will be left on for 8 hours, then standard at home shampoo will be used and rinsed off with warm water, followed by combing. At day 7, if live lice are still present, a repeat treatment will be administered.
Arm Title
Nix Creme Rinse Lice Treatment
Arm Type
Active Comparator
Arm Description
During the baseline visit (Day 0) clinical staff will first shampoo the hair and scalp using regular shampoo. They will then thoroughly rinse and towel dry the hair and scalp, and allow hair to air dry for a few minutes. Staff will shake Nix Creme Rinse Lice Treatment (1% permethrin lotion) well before applying, they will then proceed to thoroughly wet the hair and scalp with the lotion, being sure to cover the areas behind the ears and on the back of the neck. After allowing the lotion to remain in place for 10 minutes, they will rinse the hair and scalp thoroughly and dry with a clean towel. At day 7, if live lice are still present, a repeat treatment will be administered.
Intervention Type
Other
Intervention Name(s)
Vamousse Spray 'n' Go
Intervention Description
Pediculicide for topical application, active ingredient Natrum Muriaticum 2X (HPUS).
Intervention Type
Drug
Intervention Name(s)
Nix Creme Rinse Lice Treatment
Intervention Description
1% permethrin lotion for topical application.
Primary Outcome Measure Information:
Title
The proportion of subjects in a study group who are completely lice free.
Description
Lice free is defined as no live lice, adults or nymphs.
Time Frame
Day 14
Secondary Outcome Measure Information:
Title
The change in total number of live adult lice and nymphs from the baseline count in each study group.
Time Frame
Day 14

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects must have an active head lice infestation defined as: at least 1 live lice (adults and/or nymphs) present on the scalp and/or hair, as determined by a trained evaluator. Subjects must be at least two (2) years of age through 75 years of age, presenting with an active head lice infestation. Subject is male or female. Subject is in good general health based on medical history. Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children 6-17 years of age will be administered a child's Assent Form. The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, they must be willing and able to participate in receiving study product or Standard of Care. Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while participating in the study. Following application of the test product, subject agrees not to shampoo, wash or rinse their hair or scalp until 8-hour post-treatment time has been reached and documented. Subject agrees not to cut or chemically treat their hair while participating in the study. Subject agrees to follow all study instructions, including attending all follow-up appointments. Female subjects of childbearing potential must be willing to have a urine pregnancy test prior to inclusion in this study. Exclusion Criteria: History of irritation or sensitivity to Vamousse Spray 'n' Go or the components, pediculicides or hair care products. Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is >2, blisters, vesicles which, in the opinion of the investigative personnel or medical monitor, will interfere with safety and/or efficacy evaluations. Presentation at the treatment site with eczema or atopic dermatitis. Treatment for head lice (Over the Counter [OTC], home remedy and/or Prescription) in the last 30 days. Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol. Is receiving any other treatment which, in the opinion of the investigator or medical monitor, may interfere with the study results. Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy which could include household subjects. If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation and provided Standard of Care. Household members of child-bearing potential, including subjects, and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomised partner, oral birth control pills, birth control injections or patches, intra uterine devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilisation. Subjects and/or caregivers will be considered non-child-bearing if the following has occurred: full hysterectomy or bilateral oophorectomy is considered surgically sterile. Tubal ligation is not considered equivalent to female sterilisation. Participation in a previous investigational drug study within the past 30 days. Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator. Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house of apartment unit).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tim H Rivera
Phone
305-387-0081
Email
trivera@sffhrc.com
First Name & Middle Initial & Last Name or Official Title & Degree
Susel L Gonzalez Acosta
Phone
305-387-0081
Email
suselgacosta@sffhrc.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susel L Gonzalez Acosta
Organizational Affiliation
South Florida Family Health and Research Centers
Official's Role
Principal Investigator
Facility Information:
Facility Name
South Florida Family Health and Research Centers, LLC.
City
Miami
State/Province
Florida
ZIP/Postal Code
33186
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy Rivera
Phone
305-387-0081
Email
trivera@sffhrc.com
First Name & Middle Initial & Last Name & Degree
Elisabeth Rivera
Phone
305-387-0081
Email
elisabeth@sffhrc.com
First Name & Middle Initial & Last Name & Degree
Susel Gonzalez Acosta

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
22715834
Citation
Barker SC, Burgess I, Meinking TL, Mumcuoglu KY. International guidelines for clinical trials with pediculicides. Int J Dermatol. 2012 Jul;51(7):853-8. doi: 10.1111/j.1365-4632.2011.05446.x.
Results Reference
background
PubMed Identifier
26511728
Citation
Birkemoe T, Lindstedt HH, Ottesen P, Soleng A, Naess O, Rukke BA. Head lice predictors and infestation dynamics among primary school children in Norway. Fam Pract. 2016 Feb;33(1):23-9. doi: 10.1093/fampra/cmv081. Epub 2015 Oct 28.
Results Reference
background
Links:
URL
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/head-lice-infestation-developing-drugs-topical-treatment-guidance-industry
Description
Head Lice Infestation: Developing Drugs for Topical Treatment - Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research October 2016

Learn more about this trial

A Study to Evaluate the Efficacy and Safety of a Leave-in Spray in Subjects With Head Lice Infestation

We'll reach out to this number within 24 hrs